Suppression of Primary Aldosteronism and Resistant Hypertension by the Peroxisome Proliferator-activated Receptor Gamma Agonist Pioglitazone |
| |
Authors: | Yusuke Kashiwagi Yuji Mizuno Eisaku Harada Makoto Shono Sumio Morita Hirofumi Yasue Michihiro Yoshimura Mayumi Yano |
| |
Affiliation: | Division of Cardiovascular Medicine, Kumamoto Kinoh Hospital, Kumamoto Aging Research Institute, Kumamoto, Japan;Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan;Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan;Morinoki Clinic, Kumamoto, Japan. |
| |
Abstract: | The peroxisome proliferator-activated receptor gamma (PPAR γ) agonists have been reported to have antiproliferative and tumor-suppressive effects. We report a case of 55-year-old man with primary aldosteronism (PA) whose hyperaldosteronism was suppressed with the PPAR γ agonist pioglitazone. He had drug-resistant hypertension, hypokalemia, and diabetes mellitus. The diagnosis of PA was confirmed by the oral sodium loading test (20.5 μg/d of urinary aldosterone) and Captopril challenge test (19.5 ng/dL of plasma aldosterone). Computed tomography imaging revealed no apparent adrenal mass. The result of the posture stimulation test was consistent with the diagnosis of idiopathic adrenal hyperplasia. On administration of pioglitazone (30 mg/d) and nifedipine (40 mg/d), hypertension and hypokalemia improved and plasma aldosterone decreased for more than 6 months. The sodium loading test done after 6 months of the administration revealed the near normal results (11.2 ng/dL of plasma aldosterone and 13.1 μg/d of urinary aldosterone). The findings indicated that pioglitazone suppressed PA. |
| |
Keywords: | |
本文献已被 ScienceDirect 等数据库收录! |
|